Yıl: 2019 Cilt: 17 Sayı: 3 Sayfa Aralığı: 119 - 128 Metin Dili: İngilizce DOI: 10.21911/aai.461 İndeks Tarihi: 06-10-2020

Mastocytosis

Öz:
Mast cell activation diseases are common as either atopic diseases or rarely occur as mastocytosis and mast cell activation syndrome.Mastocytosis is a clonal disorder characterized by proliferation and accumulation of mast cells in various tissues, particularly the skinand bone marrow. Mast cell activation syndrome is characterized by systemic symptoms ranging from flushing and abdominal crampsto anaphylaxis secondary to mast cell degranulation. The aim of this review was to increase the awareness of the clinical features,classification, diagnosis, and treatment approaches of systemic mastocytosis. In addition, the role of mast cell activation syndrome in thedifferential diagnosis will be discussed.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Da Silva EZM, Jamur MC, Oliver C. Mast Cell Function: A new vision of an old cell. J Histochem Cytochem 2014;62(10):698- 738.
  • 2. Akin C. Mast cell activation syndromes. J Allergy Clin Immunol 2017;140 (2):349-55.
  • 3. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol 2010;126:1099-104.
  • 4. Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal. Int Arch Allergy Immunol 2012;157:215-25.
  • 5. Nettleship E, Tay W. Rare forms of urticaria. Br Med J 1869;2:323-4.
  • 6. Ellis JM. Urticaria pigmentosa; A report of a case with autopsy. Arch Pathol (Chic) 1949;48(5):426-35.
  • 7. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 2017;129(11):1420-7.
  • 8. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127(20): 2391-405.
  • 9. Méni C, Bruneau J, Georgin-Lavialle S, Le Saché de Peufeilhoux L, Damaj G, Hadj-Rabia S, et al. Paediatric mastocytosis: A systematic review of 1747 cases. Br J Dermatol 2015;172:642-51.
  • 10. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001;25:519-28.
  • 11. Escribano L, Garcia-Montero A, Sanchez-Muñoz L, Teodosio C, Alvarez‐Twose I, Jara‐Acevedo M, et al. Diagnosis of adult mastocytosis: Role for bone marrow analysis. In: KottkeMarchant K, Davis B (eds). Laboratory Hematology Practice. London: Wiley-Blackwell, 2012: 388-98.
  • 12. Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: A histopathological challenge. J Clin Pathol 2004;57:604-8.
  • 13. Castells M, Butterfield J. Mast Cell Activation Syndrome and Mastocytosis: Initial treatment options and long-term management. J Allergy Clin Immunol Pract 2019;7(4):1097-106.
  • 14. Rotolo A, Familiari U, Nicoli P, Cilloni D, Saglio G, Guerrasio A. Systemic mastocytosis: An intriguing disorder, hematologyscience and practice. In: Lawrie C (ed). Hematology-Science and Practice. In Tech 2012:467-85.
  • 15. Bonadonna P, Lombardo C, Zanotti R. Mastocytosis and allergic diseases. J Investig Allergol Clin Immunol 2014;24(5): 288-97.
  • 16. Alvarez-Twose I, González de Olano D, Sánchez-Muñoz L, Matito A, Esteban-López MI, Vega A, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010;125:1269-78.
  • 17. Gümüsburun R, Kendirlinan R, Altiner S, Toprak SK, Kuzu I, Heper A, et al. Is mastocytosis really rare as thought before? 3 case experience. EAACI Congress; 2017 June 17-21; Helsinki, Finland; 2017: p.448-50.
  • 18. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006;26:451-63.
  • 19. Picard M, Giavina-Bianchi P, Mezzano V, Castells M. Expanding spectrum of mast cell activation disorders: Monoclonal and idiopathic mast cell activation syndromes. Clin Ther 2013;35(5):548-62.
  • 20. Lyons JJ, Sun G, Stone KD, Nelson C, Wisch L, O’Brien M, et al. Mendeial n inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities. J Allergy Clin Immunol 2014; 133:1471-4.
  • 21. Aberer E, Savic S, Bretterklieber A, Reiter H, Berghold A, Aberer W. Disease spectrum in patients with elevated serum tryptase levels. Australas J Dermatol 2015;56:7-13.
  • 22. Fellinger C, Hemmer W, Wohrl S, Sesztak-Greinecker G, Jarisch R, Wantke F. Clinical characteristics and risk profile of patients with elevated baseline serum tryptase. Allergol Immunopathol (Madr) 2014;42:544-52.
  • 23. Divekar R, Butterfield J. Urinary 11beta-PGF2alpha and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders. Allergy 2015;70:1230-8.
  • 24. Denzlinger C, Haberl C, Wilmanns W. Cysteinyl leukotriene production in anaphylactic reactions. Int Arch Allergy Immunol 1995;108:158-64.
  • 25. Lueke AJ, Meeusen JW, Donato LJ, Gray AV, Butterfield JH, Saenger AK. Analytical and clinical validation of an LC-MS/ MS method for urine leukotriene E4: A marker of systemic mastocytosis. Clin Biochem 2016;49: 979-82.
  • 26. González-de-Olano D, Matito A, Orfao A, Escribano L. Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes. F1000Res. 2016;5:2666.
  • 27. Feger F, Ribadeau DA, Leriche L, Valent P, Arock M. Kit and c-kit mutation in mastocytosis: A short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002;127:110-4.
  • 28. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med 2015;373(2):163-72.
  • 29. Valent P. Mast cell activation syndromes: Definition and classification. Allergy 2013;68(4):417-24.
  • 30. Horan R, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990;85:852-5.
  • 31. Wong JT, Nagy CS, Krinzman SJ, MacLean JA, Bloch KJ. Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioe-dema. J Allergy Clin Immunol 2000;105:997- 1001.
  • 32. Broesby-Olsen S, Vestergaard H, Mortz CG, Jensen B, Havelund T, Hermann AP, et al. Omalizumab prevents anaphylaxis and improves symp-toms in systemic mastocytosis: Efficacy and safety observations. Allergy 2018; 73:230-8.
  • 33. Lieberoth S, Thomsen SF. Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab. Case Rep Med 2015;2015:903541.
  • 34. Chen M, Kim A, Zuraw B, Doherty TA, Christiansen S. Mast cell disorders: Protean manifestations and treatment responses. Ann Allergy Asthma Immunol 2018;121:128-30.
  • 35. Jagdis A, Vadas P. Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome. Ann Allergy Asthma Immunol 2014;113:115-6.
  • 36. Sokol KC, Ghazi A, Kelly BC, Grant JA. Omalizumab as a desensitizing agent and treatment in mastocytosis: A review of the literature and case report. J Allergy Clin Immunol Pract 2014;2(3):266-70.
  • 37. Castells MC, Hornick JL, Akin C. Anaphylaxis after hymenoptera sting: Is it venom allergy, a clonal disorder, or both? J Allergy Clin Immunol Pract 2015; 3:350-5.
  • 38. da Silva EN, Randall KL. Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome. J Allergy Clin Immunol Pract 2013;1:687-8.
  • 39. Rossini M, Zanotti R, Orsolini G, Tripi G, Viapiana O, Idolazzi L, et al. Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporosis Int 2016;27:2411-21.
  • 40. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 2016;374:2530-41.
  • 41. Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, et al. Imatinib for systemic mast-cell disease. Lancet 2003;362:535- 6.
  • 42. Musto P, Falcone A, Sanpaolo G, Bodenizza C, Carella AM. Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis. Leuk Res 2004;28:421-2.
  • 43. Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: A randomised, placebo-controlled, phase 3 study. Lancet 2017;389:612-20.
  • 44. DeAnelo DJ, Quiery AT, Radia D, Drummond MW, Gotlib J, Robinson WA, et al. Clinical activity in a phase 1 study of Blu-285, a potent, highly-selective inhibitor of KIT D186V in advanced systemic mastocytosis (AdvSM). Blood 2017;130(Suppl 1):2.
  • 45. Ustun , Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol 2014;32(29):3264-74.
APA gümüşburun r, Musabak U, Bavbek S (2019). Mastocytosis. , 119 - 128. 10.21911/aai.461
Chicago gümüşburun reyhan,Musabak Ugur Haci,Bavbek Sevim Mastocytosis. (2019): 119 - 128. 10.21911/aai.461
MLA gümüşburun reyhan,Musabak Ugur Haci,Bavbek Sevim Mastocytosis. , 2019, ss.119 - 128. 10.21911/aai.461
AMA gümüşburun r,Musabak U,Bavbek S Mastocytosis. . 2019; 119 - 128. 10.21911/aai.461
Vancouver gümüşburun r,Musabak U,Bavbek S Mastocytosis. . 2019; 119 - 128. 10.21911/aai.461
IEEE gümüşburun r,Musabak U,Bavbek S "Mastocytosis." , ss.119 - 128, 2019. 10.21911/aai.461
ISNAD gümüşburun, reyhan vd. "Mastocytosis". (2019), 119-128. https://doi.org/10.21911/aai.461
APA gümüşburun r, Musabak U, Bavbek S (2019). Mastocytosis. Astım Allerji İmmünoloji, 17(3), 119 - 128. 10.21911/aai.461
Chicago gümüşburun reyhan,Musabak Ugur Haci,Bavbek Sevim Mastocytosis. Astım Allerji İmmünoloji 17, no.3 (2019): 119 - 128. 10.21911/aai.461
MLA gümüşburun reyhan,Musabak Ugur Haci,Bavbek Sevim Mastocytosis. Astım Allerji İmmünoloji, vol.17, no.3, 2019, ss.119 - 128. 10.21911/aai.461
AMA gümüşburun r,Musabak U,Bavbek S Mastocytosis. Astım Allerji İmmünoloji. 2019; 17(3): 119 - 128. 10.21911/aai.461
Vancouver gümüşburun r,Musabak U,Bavbek S Mastocytosis. Astım Allerji İmmünoloji. 2019; 17(3): 119 - 128. 10.21911/aai.461
IEEE gümüşburun r,Musabak U,Bavbek S "Mastocytosis." Astım Allerji İmmünoloji, 17, ss.119 - 128, 2019. 10.21911/aai.461
ISNAD gümüşburun, reyhan vd. "Mastocytosis". Astım Allerji İmmünoloji 17/3 (2019), 119-128. https://doi.org/10.21911/aai.461